Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Year Of Surprises Shakes Up Industry Top 10

Sandoz, Mylan And Teva Switch Places At The Top

Executive Summary

In an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly-compiled global sales ranking.

You may also be interested in...



Generics Bulletin’s Top 50 Ranking For 2020

This article brings you a compilation of all the data from Generics Bulletin's recent ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.

New Faces Feature In Industry Top 50

In the third and final part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies, one or two new entrants appeared towards the bottom of the top 50.

Major Players Swap Positions Among Industry Top 50

The second part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies sees a number of major firms sliding up and down the table.

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel